Stock Watch: Debt And Biotech Do Not Mix
Debt Raises Are Poor Substitutes For Licensing Or Acquisition
Even with higher interest rates, some debt on the balance sheets of profitable biotechs is healthy. However, among loss-making biotechs and in the current environment, raising new debt has unhealthy connotations.
